Literature DB >> 25653139

Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.

Hilary A Kenny1, Madhu Lal-Nag2, Erin A White1, Min Shen2, Chun-Yi Chiang1, Anirban K Mitra1, Yilin Zhang1, Marion Curtis1, Elizabeth M Schryver1, Sam Bettis3, Ajit Jadhav2, Matthew B Boxer2, Zhuyin Li4, Marc Ferrer2, Ernst Lengyel1.   

Abstract

The tumour microenvironment contributes to cancer metastasis and drug resistance. However, most high throughput screening (HTS) assays for drug discovery use cancer cells grown in monolayers. Here we show that a multilayered culture containing primary human fibroblasts, mesothelial cells and extracellular matrix can be adapted into a reliable 384- and 1,536-multi-well HTS assay that reproduces the human ovarian cancer (OvCa) metastatic microenvironment. We validate the identified inhibitors in secondary in vitro and in vivo biological assays using three OvCa cell lines: HeyA8, SKOV3ip1 and Tyk-nu. The active compounds directly inhibit at least two of the three OvCa functions: adhesion, invasion and growth. In vivo, these compounds prevent OvCa adhesion, invasion and metastasis, and improve survival in mouse models. Collectively, these data indicate that a complex three-dimensional culture of the tumour microenvironment can be adapted for quantitative HTS and may improve the disease relevance of assays used for drug screening.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25653139      PMCID: PMC4427252          DOI: 10.1038/ncomms7220

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  34 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

Review 2.  Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer.

Authors:  Maurie Markman
Journal:  Gynecol Oncol       Date:  2013-05-30       Impact factor: 5.482

Review 3.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

4.  Drug Repurposing from an Academic Perspective.

Authors:  Tudor I Oprea; Julie E Bauman; Cristian G Bologa; Tione Buranda; Alexandre Chigaev; Bruce S Edwards; Jonathan W Jarvik; Hattie D Gresham; Mark K Haynes; Brian Hjelle; Robert Hromas; Laurie Hudson; Debra A Mackenzie; Carolyn Y Muller; John C Reed; Peter C Simons; Yelena Smagley; Juan Strouse; Zurab Surviladze; Todd Thompson; Oleg Ursu; Anna Waller; Angela Wandinger-Ness; Stuart S Winter; Yang Wu; Susan M Young; Richard S Larson; Cheryl Willman; Larry A Sklar
Journal:  Drug Discov Today Ther Strateg       Date:  2011

5.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

6.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Authors:  Hilary A Kenny; Swayamjot Kaur; Lisa M Coussens; Ernst Lengyel
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 7.  Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.

Authors:  Hilary A Kenny; Songuel Dogan; Marion Zillhardt; Anirban K Mitra; S Diane Yamada; Thomas Krausz; Ernst Lengyel
Journal:  Cancer Treat Res       Date:  2009

Review 8.  The tumor microenvironment is a dominant force in multidrug resistance.

Authors:  Ana Luísa Correia; Mina J Bissell
Journal:  Drug Resist Updat       Date:  2012-02-13       Impact factor: 18.500

9.  Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Authors:  Hilary A Kenny; Chun-Yi Chiang; Erin A White; Elizabeth M Schryver; Mohammed Habis; Iris L Romero; Andras Ladanyi; Carla V Penicka; Joshy George; Karl Matlin; Anthony Montag; Kristen Wroblewski; S Diane Yamada; Andrew P Mazar; David Bowtell; Ernst Lengyel
Journal:  J Clin Invest       Date:  2014-09-09       Impact factor: 14.808

10.  Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia.

Authors:  Todd W Ridky; Jennifer M Chow; David J Wong; Paul A Khavari
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

View more
  58 in total

1.  Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells.

Authors:  Molly J Carroll; Kaitlin C Fogg; Harin A Patel; Harris B Krause; Anne-Sophie Mancha; Manish S Patankar; Paul S Weisman; Lisa Barroilhet; Pamela K Kreeger
Journal:  Cancer Res       Date:  2018-05-08       Impact factor: 12.701

2.  Make better, safer biomaterials.

Authors:  Nicholas A Peppas; Ali Khademhosseini
Journal:  Nature       Date:  2016-12-14       Impact factor: 49.962

Review 3.  Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.

Authors:  Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss
Journal:  Med Res Rev       Date:  2016-12-07       Impact factor: 12.944

4.  Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.

Authors:  Jeff Hirst; Harsh B Pathak; Stephen Hyter; Ziyan Y Pessetto; Thuc Ly; Stefan Graw; Devin C Koestler; Adam J Krieg; Katherine F Roby; Andrew K Godwin
Journal:  Cancer Res       Date:  2018-06-11       Impact factor: 12.701

Review 5.  Targeting dormant micrometastases: rationale, evidence to date and clinical implications.

Authors:  Robert E Hurst; Anja Bastian; Lora Bailey-Downs; Michael A Ihnat
Journal:  Ther Adv Med Oncol       Date:  2016-03       Impact factor: 8.168

6.  Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis.

Authors:  Hilary A Kenny; Madhu Lal-Nag; Min Shen; Betul Kara; Dominik A Nahotko; Kristen Wroblewski; Sarah Fazal; Siquan Chen; Chun-Yi Chiang; Yen-Ju Chen; Kyle R Brimacombe; Juan Marugan; Marc Ferrer; Ernst Lengyel
Journal:  Mol Cancer Ther       Date:  2019-09-27       Impact factor: 6.261

7.  Machine learning on drug-specific data to predict small molecule teratogenicity.

Authors:  Anup P Challa; Andrew L Beam; Min Shen; Tyler Peryea; Robert R Lavieri; Ethan S Lippmann; David M Aronoff
Journal:  Reprod Toxicol       Date:  2020-05-16       Impact factor: 3.143

8.  Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.

Authors:  Peter C Hart; Preety Bajwa; Hilary A Kenny
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies.

Authors:  Emily J Chadwick; David P Yang; Mariella G Filbin; Emanuele Mazzola; Yu Sun; Oded Behar; Maria F Pazyra-Murphy; Liliana Goumnerova; Keith L Ligon; Charles D Stiles; Rosalind A Segal
Journal:  J Vis Exp       Date:  2015-11-07       Impact factor: 1.355

10.  Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.

Authors:  Yilin Zhang; Shravan Kumar Sriraman; Hilary A Kenny; Ed Luther; Vladimir Torchilin; Ernst Lengyel
Journal:  Mol Cancer Ther       Date:  2016-07-27       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.